SRRA - SRRA STOCK NEWS

Sierra Oncology, Inc. (SRRA) announced the grant of stock options to a new employee, amounting to 50,000 shares with an exercise price of $16.73 per share, equating to the current stock price. This initiative falls under Sierra's 2018 Equity Inducement Plan, aimed at attracting new talent. The options will vest over four years, contingent on the employee's continued employment. This move underscores Sierra's objective to enhance its workforce while navigating the challenges of clinical development and capital resource management.

Sierra Oncology (SRRA) reported its financial results for the year ended December 31, 2020, highlighting key developments in its Phase 3 MOMENTUM trial. Enrollment is on track for mid-2021, with top-line data expected in H1 2022. Financially, the company experienced a GAAP net loss of $80.9 million, a slight improvement compared to $88.3 million in 2019. Research and development expenses totaled $45.1 million, down from $53.2 million in the previous year. Cash reserves stood at $104.1 million, down from $147.5 million. Executive appointments were made to strengthen commercial execution.

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on targeted therapies for rare cancers, announced participation in three investor conferences in March 2021. CEO Stephen Dilly will present at both the HC Wainwright Life Sciences Conference on March 9 and the Oppenheimer Healthcare Conference on March 17. Chief Development Officer Barbara Klencke will speak at the Roth Conference on March 15. All presentations will be webcast and accessible through the company's website.

Sierra Oncology, Inc. (SRRA) will have its President and CEO, Stephen Dilly, present at the LifeSci Partners Precision Oncology Day on February 17, 2021. The company focuses on targeted therapies for rare cancers and is advancing its development of momelotinib, aimed at changing the cancer treatment paradigm. A replay of the presentation will be accessible post-event on the company's website. The press release also includes forward-looking statements regarding the company's clinical development activities and potential challenges, including the risk of insufficient cash resources and impacts from COVID-19.

Sierra Oncology, Inc. (SRRA) announced the grant of a stock option to a new employee under its 2018 Equity Inducement Plan. The option allows the purchase of 50,000 shares at an exercise price of $14.67 per share, matching the stock's closing price on the grant date. The vesting schedule includes 25% vesting on the first anniversary and the remaining 75% over 36 months, contingent on continued employment. This grant aims to incentivize new talent as Sierra focuses on developing targeted therapies for rare cancers.

Sierra Oncology (SRRA) announced that CEO Stephen Dilly will present at the H.C. Wainwright 2021 BioConnect Virtual Conference from January 11-14, 2021. The presentation will be available online starting at 6:00 am ET on January 11, with a replay accessible on the company’s website thereafter. Sierra Oncology focuses on developing targeted therapies for rare cancers, emphasizing its commitment to advancing innovative treatments that address the root causes of disease. For more details, visit www.SierraOncology.com.

Sierra Oncology, Inc. (SRRA) presents updated efficacy analyses of momelotinib for myelofibrosis patients with thrombocytopenia at the 2020 American Society of Hematology Annual Meeting. The data shows momelotinib's safety and efficacy are unaffected by baseline platelet counts, unlike ruxolitinib, which exhibited decreased activity in patients with lower platelet levels. The analysis indicates statistically significant improvements in total symptom scores, splenic response, and transfusion independence rates with momelotinib. The company is focused on completing enrollment in the pivotal Phase 3 MOMENTUM study, aiming for regulatory approval.

Sierra Oncology, Inc. (SRRA) presented updated overall survival data for momelotinib at the 2020 ASH Annual Meeting. The data showed robust overall survival (OS) in both JAKi-naïve and ruxolitinib-treated patients. Key results from the Phase 3 SIMPLIFY studies indicated a median OS not reached in the momelotinib arm compared to 53.1 months for the control in JAKi-naïve patients. Additionally, transfusion independence rates were significantly higher in the momelotinib group. The compound demonstrated favorable safety profiles, contributing to the company's ongoing efforts to address unmet needs in myelofibrosis treatment.

Sierra Oncology (SRRA) will host an analyst and investor event on December 16, 2020, featuring key experts in myelofibrosis, including Jean-Jacques Kiladjian and Ruben Mesa. The event will present updated data on momelotinib, a promising treatment for myelofibrosis currently undergoing Phase 3 trials. The data presentation will be followed by a Q&A session. Momelotinib has received FDA Fast Track designation, indicating its potential importance in treating this debilitating condition. Top-line results from the MOMENTUM trial are expected in H1 2022.